Merck's combination cancer therapy succeeds in late-stage study
Send a link to a friend
 [November 22, 2022]
(Reuters) - Merck & Co Inc said on Tuesday its therapy involving cancer
drug Keytruda in combination with chemotherapy met main goal of a
late-stage study for treating a type of cancer of the esophagus.
[to top of second column]
|
 (Reporting by Raghav Mahobe in
Bengaluru; Editing by Anil D'Silva)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
